Merck Archives - Page 6 of 8 - Medical Design Sourcing

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies also overcame COVID-19-related clinical trial disruption and staffing hurdles, driving unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

One of the most notable achievements involved the mRNA vaccines from Pfizer/BioNTech and Moderna, according to analyst Mani Foroohar at SVB Leerink.

Other achievements, according to Foroohar, includ…

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.

Merck spinoff Organon to acquire Alydia Health for up to $240M

Merck announced today that it entered into an agreement for its spinoff Organon to acquire Alydia Health for up to $240 million.

Alydia Health develops treatments focusing on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding, according to a news release. The company develops the Jada system for controlling and treating abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.

The deal is slated to close after Organon has successfully spun off from Merck as a standalone, publicly-traded company, a move expected to be completed late in the second quarter of 2021.

Organon’s agreement to acquire Alydia Health includes up to $240 million total consideration, with $215 million being spent upfront, plus a $25 million contingent milestone payment. Of the upfront payment, $50 million will be paid prior to Organon’s spinoff, with the remaining $1…

Report: Biden to buy 100M additional doses of J&J COVID-19 vaccine

President Joe Biden is reportedly set to announce plans to purchase an additional 100 million doses of Johnson & Johnson’s (NYSE:JNJ) COVID-19 vaccine.

An NBC News report said that Biden is set to announce the purchase of the single-dose vaccines on Wednesday, according to two officials from his administration.

Get the full story at our sister site, Drug Discovery & Development.

Merck moving to Phase 2 study of drug-eluting implant to prevent HIV infection

Merck (NYSE:MRK) today announced positive results from a Phase 1 study of its subdermal drug-eluting implant for preventing HIV-1 infection.

The investigational implant has the potential for extended administration of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Merck moving to Phase 2 study of drug-eluting implant to prevent HIV infection

Merck (NYSE:MRK) today announced positive results from a Phase 1 study of its subdermal drug-eluting implant for preventing HIV-1 infection.

The investigational implant has the potential for extended administration of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine

President Joe Biden is reportedly set to announce a partnership in which Merck (NYSE:MRK) will make Johnson & Johnson’s (NYSE:JNJ) recently approved COVID-19 vaccine.

The Washington Post reported that the agreement between the two competitors will boost the supply of the single-dose vaccine from J&J’s Janssen subsidiary, which received FDA emergency use authorization last week.

Get the full story at our sister site, Pharmaceutical Processing World.

Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine

President Joe Biden is reportedly set to announce a partnership in which Merck (NYSE:MRK) will make Johnson & Johnson’s (NYSE:JNJ) recently approved COVID-19 vaccine.

The Washington Post reported that the agreement between the two competitors will boost the supply of the single-dose vaccine from J&J’s Janssen subsidiary, which received FDA emergency use authorization last week.

Get the full story at our sister site, Pharmaceutical Processing World.

Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine

President Joe Biden is reportedly set to announce a partnership in which Merck (NYSE:MRK) will make Johnson & Johnson’s (NYSE:JNJ) recently approved COVID-19 vaccine.

The Washington Post reported that the agreement between the two competitors will boost the supply of the single-dose vaccine from J&J’s Janssen subsidiary, which received FDA emergency use authorization last week.

According to the report, anonymous officials told The Post that, upon the realization that J&J was behind on vaccine production in the early days of the Biden administration, they began looking for additional manufacturing capacity, landing on Merck as an option after the company was unable to produce its own COVID-19 vaccine.

Merck is set to provide two U.S. facilities for producing J&J vaccine doses, with one offering fill-finish services and the other actually making the vaccine. According to the report, this could potentially double the production capacit…

Merck to supply lipids to boost Pfizer-BioNTech COVID-19 vaccine production

Merck (NYSE:MRK) announced that it’s expanding its partnership with BioNTech (NSDQ:BNTX) to supply lipids for the Pfizer (NYSE:PFE)/BioNTech COVID-19 vaccine.

The agreement will accelerate the supply of lipids and increase the amount of lipid delivery toward the end of 2021 so they can be used as part of the drug delivery system of mRNA therapies to the body, helping to make the vaccine effective, according to a news release.

Darmstadt, Germany-based Merck said it has worked to expand its already high lipid production capacity as it is currently combining with BioNTech to define exact requirements as they aim for a timely execution of the effort.

“What unites BioNTech and Merck KGaA, Darmstadt, Germany, is our strong belief in mRNA technology and our trustful collaboration in vaccine development,” Merck chairman & CEO Stefan Oschmann said in the release. “We are convinced that now is the time to pull together to supply as much vacci…